Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Enveric Biosciences, Inc.

Get SEC filing alerts via email and in your feed for Enveric Biosciences, Inc.

ENVB

Enveric Biosciences, Inc.

About Enveric Biosciences, Inc.

Enveric Biosciences develops neuroplastogenic small-molecule therapeutics targeting mental health disorders such as depression, anxiety, and addiction. Utilizing proprietary platforms like the Psybrary, the company focuses on novel psychedelic-inspired compounds with potential therapeutic benefits without hallucinogenic effects. It advances preclinical and clinical research, seeks regulatory approvals, and collaborates with academic and industry partners to bring innovative neuropsychiatric treatments to market.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Enveric Biosciences, Inc.

1
1
Enveric Biosciences, Inc. Enveric Biosciences Reports $1.6 Million Net Loss in Q1 2026, Focuses on R&D Funding

Via official filing (AI summary) | 20 days ago | 0 comments

2
1
Enveric Biosciences, Inc. Enveric Biosciences Reports $8.77 Million Net Loss for Fiscal Year 2025

Via official filing (AI summary) | 2 months ago | 0 comments

3
1
Enveric Biosciences, Inc. Enveric Biosciences Reports Q3 2025 Financial Results with $3.39 Million Net Loss

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Enveric Biosciences, Inc. Enveric Biosciences Reports Increased Net Loss and Focus on Drug Development

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Enveric Biosciences, Inc. Enveric Biosciences Reports Q1 2025 Financial Results with Improved Cash Position

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Enveric Biosciences, Inc. Enveric Biosciences Reports $9.6 Million Net Loss for Fiscal Year 2024, Out-licenses EVM201 Program

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Enveric Biosciences, Inc. Enveric Biosciences Reports Improved Financials, Reduced Losses in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments